Kraig Biocraft Laboratories Highlighted by Tech Times for Advancing Spider Silk from Science Fiction Toward Commercial Reality
Kraig Biocraft Laboratories spotlights media coverage linking its transgenic silkworm platform and recent 30% output gain to spider silk commercialization.
Rhea-AI Summary
Kraig Biocraft Laboratories (KBLB) highlighted a recent Tech Times feature that examines the scientific basis and commercialization path of its recombinant spider silk platform. The article explains how Kraig Labs uses genetically engineered Bombyx mori silkworms as biological production systems, leveraging their existing silk glands to spin spider silk proteins at scale. Kraig Labs recently reported a new production record on August 24, 2026, lifting output by more than 30% over its prior milestone, achieved during the technically challenging rainy season. The company positions this as evidence that its silkworm-based platform can move spider silk from science fiction toward commercial reality. Its work in scaling spider silk production was also featured on the cover of the March 2026 issue of National Geographic.
Positive
- Production output surpassed the prior milestone by more than 30% as of August 24, 2026.
- New output record was achieved during the rainy season, described as a technically demanding production period.
- Kraig Labs’ spider silk platform received in-depth coverage from Tech Times and a March 2026 National Geographic cover feature, raising visibility.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Feature Explores the Real Biology Behind Recombinant Spider Silk and the Scientific Case for Kraig Labs' Production Platform
ANN ARBOR, Mich., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today highlighted recent coverage by Tech Times examining the scientific gap between fictional biology and real-world advances in recombinant spider silk production.
The August 31, 2026 Tech Times feature, Spider-Man: Brand New Day’s Silk Is Commercially Real; Wrist Location Breaks Biology, by Philip Nickell, takes a detailed look at the biology underlying spider silk. It connects popular culture's take on biological innovation to the real scientific and commercialization work underway today.
This in-depth article addresses a central element in commercializing spider silk. Producing spider silk proteins is only the first step. Engineering a practical biological system that can produce silk at scale is the key driver for broad commercialization. Rather than recreating a spider's silk-producing anatomy from scratch, Kraig Labs uses the naturally evolved silk-producing machinery of the silkworm. Genetic engineering introduces key spider silk proteins into that existing biological platform.
As the article notes, Kraig Labs uses genetically engineered Bombyx mori silkworms as biological production systems. This model leverages the silkworms' sophisticated silk glands and spinning architecture.
That distinct strategy sits at the core of Kraig Labs' technology. The challenge was never proving that spider silk proteins can be produced. It was building a production platform that delivers recombinant spider silk at meaningful scale, with commercially relevant properties.
Kraig Labs recently reported strong progress on that front. On August 24, 2026, the Company announced a new production record, increasing output more than
The Tech Times feature offers a compelling lens on that progress. By explaining why fictional wrist spinnerets are biologically implausible, and how transgenic silkworms offer a scientifically credible path to commercial spider silk production. The article places Kraig Labs' technology within the broader history of spider silk research and its leading role in its commercialization.
“We appreciate Tech Times for bringing this level of scientific depth to the conversation around spider silk. This article captures exactly what we set out to build,” said Kim Thompson, Founder and CEO of Kraig Biocraft Laboratories. “We took a proven biological system and gave it a new purpose. That work is now producing real silk, at real scale, moving toward real commercial applications.”
Thompson added, "The distinction between producing spider silk proteins and reproducing the biological machinery that spins them is exactly what our technology does. This article highlights what we’ve known all along; the key to unlocking spider silk's commercial potential was a cost-effective and scalable production platform.”
Kraig Labs' technology is built around a genetically engineered silkworm that produces recombinant spider silk. From single grams to metric tons, the Company has turned a scientific breakthrough into a functioning production platform.
The Company's leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.
Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.
You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about recent Kraig Labs advancements, please watch the Company's investor updates at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Tech Times
Tech Times goes beyond the announcement to examine the science, technology, business dynamics, and real-world implications behind the developments shaping tomorrow. While traditional coverage often focuses on the headline moment—a product launch, funding round, research result, or corporate announcement—Tech Times explores what comes before and after, following the research, technical decisions, competitive forces, and second-order consequences that determine where a story ultimately leads. Its cross-disciplinary approach reflects how STEM actually works, recognizing that advances in science, healthcare, materials, computing, and business increasingly intersect. Tech Times is committed to precision, depth, and context, providing coverage that is useful to practitioners while remaining accessible to anyone driven by genuine curiosity. Owned and operated by Tech Times Media Inc., headquartered in New York City with newsrooms across the United States, Europe, and Asia, Tech Times is independently operated and editorially driven, with sponsored content clearly identified.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com
